Next Generation Dx Summit

ADX_BDX_Track_Header


Day 1 | Day 2 | Short Courses | Download Brochure 

WEDNESDAY, AUGUST 20

7:15 am Registration


7:30 – 8:25 Problem-Solving Breakout Discussions with Continental Breakfast

These interactive discussion groups are open to all attendees, speakers, sponsors, & exhibitors. Participants choose a specific breakout discussion group to join. Each group has a moderator to ensure focused discussions around key issues within the topic. This format allows participants to meet potential collaborators, share examples from their work, vet ideas with peers, and be part of a group problem-solving endeavor. The discussions provide an informal exchange of ideas and are not meant to be a corporate or specific product discussion.

Latin American Market Access for Personalized Medicine

Carlos Gil Ferreira, M.D., Executive Director, INOVA-CANCER; Director, Clinical Research, Brazilian National Cancer Institute

  • Personalized medicine in LATAM: how aware of the topic are medical oncologists in the region
  • The barrier of reimbursement
  • Sample quality and molecular pathology in the region

Clinical Perspectives of Next Generation Sequencing

Divyaa Ravishankar, Senior Industry Analyst, North America & Europe, Life Sciences, Frost & Sullivan

  • Potential challenges in Developing a NGS based Companion Diagnostic test. 
  • Are we going to see more NGS platforms getting FDA and CE clearance in the next few years? 
  • Within Oncology which of the cancer types will see the uptake of NGS based tests at the earliest and why? 
  • What kind of business models / strategy partnerships we can observe between NGS tool makers and drug companies in future?
     

New Partnership Paradigms in Companion Diagnostics/Personalized Medicine

Matthew J. Hawryluk, Ph.D., Senior Director, Corporate & Business Development, Foundation Medicine, Inc.

  • Increasing the value for the diagnostic partners and maximizing the outcomes for the pharma partners
  • Deliverables and the desired outcomes
  • Average costs and financial structures
 

GOING GLOBAL AND GOING NGS: REGULATORY PERSPECTIVE 

8:25 Chairperson’s Opening Remarks

Catherine BrownsteinCatherine Brownstein, M.D., Harvard Medical School and Boston Children’s Hospital

8:30 Regulatory Challenges in Co-Development of CDX and Drugs: A Diagnostics Perspective

Tracy Bush, Ph.D., Director and Global Coordinator, Companion Diagnostics, Regulatory Affairs, Roche Diagnostics

Globally, Pharma and Diagnostics operate under different regulations, with different statutory requirements and timelines. Drug and diagnostic codevelopment timelines are not always optimally aligned to meet the needs of the various regulatory processes. This presentation will explore various regulatory challenges that ensue when the standard diagnostics development pathway is asked to flex to meet the needs of a drug clinical program; and offer possible pathways for their resolution.

9:00 Global Clinical Trial Design Considerations When Incorporating a Companion Diagnostic

Sabah MalekSabah Malek, Associate Director, Global Regulatory Affairs, Eisai, Inc.

A well thought-out clinical trial, especially one that will be the basis for the approval of two products from different divisions within FDA not to mention different governing bodies in the EU, is imperative for a successful launch. Since the recognition of personalized medicine, FDA and other health authorities have been resolute regarding the ideal co-development plan for targeted therapeutics and companion diagnostics. However in practice, this proves to be difficult for numerous reasons. One example of this is the identification of the need for a companion diagnostic in a mature program.

9:30 NGS-Based Companion Diagnostics: Points to Consider

Jennifer Dickey, RAC, Ph.D., Office of In Vitro Diagnostics, DIHD, US Food and Drug Administration

While there has not yet been a companion diagnostic approval of a Next Gen Sequencing-based assay, there has been considerable interest in using gene panels or single gene sequencing to select the patient population that will benefit from targeted therapy. This talk will highlight points to consider in developing a NGS-based companion diagnostics  

  10:00 Sponsored Presentation (Opportunity Available)

 

Incell Dx10:15 Cellular Multiplex™, a Pathway Approach to Companion Diagnostics

bruce_incelldxBruce K. Patterson, M. D., CEO, InCellDx, Inc

Cellular Multiplex™, a diagnostic approach that allows multiplexing of proteins using antibodies, mRNA using in situ hybridization, and DNA cell cycle using dyes. Morphologic measurements such as mean corpuscular volume, nuclear area, and nuclear-to-cytoplasmic ratio can be determined. It provides prognostic information, companion diagnostic functions when deployed in our novel bioinformatics algorithms.

10:30 Coffee Break in Exhibit Hall with Poster Viewing


PLENARY SESSION: Think Tank on Next-Generation Sequencing Diagnostics 

11:00 Chairperson’s Opening Remarks

Harry Glorikian, Healthcare Consultant

11:10 Discussion: Regulatory Review of Clinical Sequencing Assays

Harry GlorikianModerator: Harry Glorikian, Healthcare Consultant






Jennifer DickeyGuest Speaker: Jennifer Dickey, RAC, Ph.D., Office of In Vitro Diagnostics, DIHD, US Food and Drug Administration






In November of 2013, the FDA issued the first clearances of Next Gen Sequencing- (NGS) based assays. There have additionally been a number of clinical trials approved recently that utilize NGS-based assays for patient enrollment or stratification. In light of the expanding roles that new sequencing technologies are playing in clinical decision making, this talk will focus on critical elements that FDA considers when evaluating NGS validation using the recent clearances/approvals as examples. There will also be a discussion of any new communications that FDA has issued in regard to the regulatory review of NGS- based assays. Following the discussion there will be a Q&A with the audience.

11:55 Next-Generation Sequencing in Clinical Practice: Case Reports of Clinical Utility and Reimbursement 

Elaine LyonModerator: Elaine Lyon, Ph.D., Medical Director, Molecular Genetics, ARUP






Case Presenters:

Andrea Ferreira-Gonzalez Andrea Ferreira-Gonzalez, Ph.D., Professor, Pathology; Director, Molecular Diagnostics Lab, Virginia Commonwealth University






Madhuri HegdeMadhuri Hegde, Ph.D., FACMG, Professor, Human Genetics; Executive Director, Emory Genetics Laboratory, Emory University School of Medicine






The landscape of next-generation sequencing diagnostics is changing rapidly. Clinical laboratories are offering highly complex tests using new technologies, but face challenges in reimbursement. To be reimbursed for these tests, laboratories will need to address clinical utility as well as clinical validity. Clinical cases that demonstrate the utility of genomic oncological and inherited disease testing will be presented. Experiences with reimbursement of these tests will be discussed.

12:40 pm Close of Conference



Day 1 | Day 2 | Short Courses | Download Brochure 

Japan-Flag Korea-Flag China-Simplified-Flag China-Traditional-Flag 

2014 Brochure

2014 Brochure 

Premier Sponsors

Affymetrix 

Luminex 

Certara 



Related Products

MDX_Logo_150x150